Page 3 - Les meilleurs doctors traitant la maladie suivante : Mélanome - TOP -100 des médecins

Spécialisé en chirurgie laparoscopique et bariatrique avancée à l'Université d'Istanbul – l'une des meilleures institutions médicales de Turquie.

• Plus de 20 ans d'expérience chirurgicale
• Formé dans plusieurs universités prestigieuses, dont Ondokuz Mayıs et l'Université d'Istanbul
• Se spécialiser dans les techniques de chirurgie oncologique du cancer
• Suivre une formation avancée en chirurgie laparoscopique en 2010

Le Dr Alemdar se spécialise dans le traitement du mélanome avec plus de 7 ans d'expérience en oncologie à l'hôpital universitaire d'Akdeniz.

• Certifié en oncologie médicale
• Formation approfondie à l'Université d'Akdeniz – l'une des principales facultés de médecine de Turquie
• Pratique spécialisée au complexe hospitalier Medical Park Antalya
• Expérimenté dans les cas complexes de mélanome

Le Dr Inta Jaunalksne est spécialisée dans la virothérapie, une approche immunologique de pointe pour le traitement du mélanome.

• Plus de 30 ans d'expérience en immunologie
• Chef du centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Diplômée de l'Institut de médecine de Riga
• Internat en médecine interne

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Prof. Dr. Önder SÜRGİT is a General Surgeon in the General Surgery Clinic. Working hours: 09:00–18:00. Core practice areas include laparoscopic surgery, cancer surgery, and bariatric surgery.

Graduated from Hacettepe Faculty of Medicine in 1995. Academic title: Professor. Served as Instructor Surgeon at ITEM (Advanced Medical Technologies Training Center). Held faculty roles at Turgut Özal University and Atılım University, Faculties of Medicine. Also worked at Ankara Medicana Hospital and Optimed Health Group. Foreign language: English.

Le Dr Erkan Karatas est spécialisé dans les chirurgies complexes de la tête et du cou, avec une formation internationale approfondie en Europe et aux États-Unis.

• Formation dans des institutions de premier plan, notamment l'Université d'État de l'Ohio et la Faculté de médecine de Hanovre
• Membre de plusieurs associations prestigieuses d'oto-rhino-laryngologie et de chirurgie de la tête et du cou
• Spécialisation dans les procédures d'otologie et de neurotologie
• Participer à des programmes internationaux d'enseignement et de formation médicale

Chargé de recherche senior en cancer de la peau au St John's Institute of Dermatology – formé dans les meilleurs hôpitaux britanniques et israéliens, spécialisé dans le mélanome.

• Bourse de recherche (Fellowship) au St John's Institute, un centre de pointe pour le cancer de la peau
• Enseignement sur le mélanome au King's College de Londres
• Membre de l'European Academy of Dermatology and Venereology
• Se spécialiser dans le diagnostic et le traitement chirurgical des cancers de la peau

Le Dr Bar-Sela est le chef adjoint du département d'oncologie du centre médical Rambam.

• Diriger une équipe spécialisée au sein d'un grand hôpital universitaire
• Se concentrer sur le traitement du mélanome
• Superviser des programmes de traitement avancés pour les patients cancéreux

Le Dr Michael Lotem dirige le centre d'immunothérapie du mélanome et du cancer au centre médical Hadassah, mettant au point de nouveaux traitements pour les patients atteints de mélanome.

• Responsable du centre d'immunothérapie du mélanome et du cancer
• Spécialisation dans les immunothérapies innovantes pour le mélanome
• Direction d'une équipe de cliniciens et de chercheurs
• Priorité à la recherche translationnelle ayant un impact clinique immédiat

Le Dr Jesus Soberino se spécialise dans l'immunothérapie du mélanome, ayant contribué à des essais pivots qui ont révolutionné le traitement du mélanome avec des médicaments comme le Pembrolizumab et le Nivolumab.

• 14 ans d'expérience en oncologie avec une spécialisation sur le mélanome
• Membre de l'Unité du Mélanome à l'Hôpital Universitaire Vall d'Hebron et au VHIO
• Participation à des essais cliniques ayant mené à des médicaments approuvés par la FDA
• Expertise dans les traitements d'immunothérapie pour le mélanome métastatique

Spécialisée en radiothérapie, la Dre Zalmanova propose des traitements ciblés au centre médical Assuta.

• Être experte en techniques de radiothérapie avancées
• Personnaliser les plans de traitement pour chaque patient
• Mettre l'accent sur la précision et le confort du patient

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Le Dr Tepper dirige l'ensemble du centre d'oncologie du célèbre centre médical Assuta en Israël, apportant une supervision stratégique aux cas complexes de mélanome.

• Médecin-chef et oncologue senior avec des années d'expérience ciblée
• Se spécialiser dans la gestion avancée des cancers de la peau comme le mélanome
• Prodiguer des soins au sein d'un grand réseau hospitalier privé de haute technologie
• Apporter une perspective de leadership à la création de plans de traitement personnalisés